Condensed Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 144,717	$ 82,248
Accounts receivable	67,824	48,494
Prepaid clinical development costs	499	193
Inventories, net	80,102	65,623
Other prepaid and current assets	14,413	4,507
Total current assets	307,555	201,065
Property and equipment, net	281	0
Right of use operating lease assets	6,222	4,675
Intangible assets	56	56
Total assets	314,114	205,796
Current liabilities:
Accounts payable	34,864	31,718
Accrued clinical development costs	3,546	3,441
Accrued variable consideration	52,003	34,284
Other accrued liabilities	19,247	24,998
Revenue interest liability	0	34,828
Royalty sale liability	38,394	0
Deferred revenue from collaborations	15,078	25,402
Operating lease liabilities	2,741	1,553
Total current liabilities	165,873	156,224
Convertible notes, net of issuance costs	262,922	261,596
Revenue interest liability	0	239,950
Royalty sale liability	252,229	0
Operating lease liabilities	3,299	3,020
Total liabilities	684,323	660,790
Commitments and contingencies (Note 5)
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized and no shares issued or outstanding as of September 30, 2024 and December 31, 2023	0	0
Common stock, $0.001 par value; 480,000,000 shares authorized as of September 30, 2024 and 480,000,000 shares authorized as of December 31, 2023; 197,434,696 shares issued at September 30, 2024 and 120,204,513 shares issued at December 31, 2023	195	118
Additional paid-in capital	1,264,305	1,149,170
Treasury stock, at cost; 1,994,198 shares at September 30, 2024 and December 31, 2023	(54,998)	(54,998)
Accumulated deficit	(1,579,711)	(1,549,284)
Total stockholders’ deficit	(370,209)	(454,994)
Total liabilities and stockholders’ deficit	$ 314,114	$ 205,796